The Growing Threat of NDM-Producing E. Coli With Penicillin-Binding Potein 3 Mutations in the United States—Is There a Potential Role for Durlobactam?

Abstract We report identification of 5 patients with infections caused by NDM-5-producing Escherichia coli harboring PBP3 mutations that showed reduced susceptibility to aztreonam-avibactam and cefiderocol. Durlobactam, a novel diazabicyclooctane β-lactamase inhibitor, demonstrated minimum inhibitory concentrations ranging from 0.5 to 2 µg/mL supporting future investigations into a potential role in clinical management.